Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks That Are Overvalued

By Jason Hall, Neha Chamaria, and George Budwell – Sep 12, 2016 at 11:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Three of our experts think that GW Pharmaceuticals, Coca-Cola, and Caterpillar stocks are way too expensive right now. Keep reading to find out why.


Every stock has a fair price. Pay too much, and you might get burned. Image source: Getty Images.

One of the biggest mistakes you can make as an investor is paying too much for a stock that's not worth the premium. And with the market near its all-time highs, there are a lot of stocks that fall in the "expensive" bucket. The catch? Sometimes those expensive stocks can make great investments -- if the premium you pay is for a premium business generating returns that warrant the high price. 

But too many times, investors make the mistake of paying a premium for a business that isn't worth it. With that in mind, we asked three of our experts to weigh in on the topic, and suggest equities they don't think justify their high P/E ratios. Their suggestions: a speculative upstart, an industrial stalwart, and one of the most well-known companies in the world. Keep reading to learn why our experts say these  stocks are so overvalued. 

This marijuana stock's valuation is sky high

George Budwell: While the biotech bubble might have burst this year, shares of GW Pharmaceuticals (NASDAQ: GWPH), which is developing marijuana-based treatments, haven't noticed. In fact, the drugmaker's shares have gained an eye-popping 41% this year alone:

GWPH Chart

GWPH data by YCharts

Although GW's steady march upwards has been tied to two positive late-stage readouts this year for its childhood epilepsy drug candidate, Epidiolex, there's good reason to believe that the market has simply gotten ahead of itself on this one.

The bottom line is that GW's shares are probably trading somewhere around 7 times Epidiolex's peak sales right now. That's a rather rich valuation any way you cut it. But the fact that GW is developing a novel -- and as of yet commercially unproven -- type of product certainly doesn't help matters. In short, the all-things-marijuana craze appears to have juiced GW's valuation beyond the company's underlying fundamentals or its near-term growth prospects, perhaps setting it up for a sizable pullback.

Too soon to jump on to this industrial heavyweight 

Neha Chamaria: I'm pretty surprised by Caterpillar Inc.'s (CAT) run up in recent months. The heavy-equipment maker's up almost 15% since mid-May. Funnily enough, its growth prospects come nowhere close to justifying the rally in the stock, making it appear substantially overvalued today.

At current prices, Caterpillar is trading at an insane 43 times trailing earnings. Worse yet, the company's earnings are projected to grow only by low- to mid-single digit percentages over the next five years. Those muted estimates don't surprise me: Two of Caterpillar's businesses are facing severe headwinds, while the third isn't in its best shape either.

The mining industry is still in the doldrums, even as low oil prices have stalled spending in the oil and natural gas industry. Both industries are under significant pressure, posing a major challenge for Caterpillar's resource extraction and energy and transportation businesses going forward. Caterpillar's construction industries business may be better off, but it's unlikely to be sufficient to offset the weakness in the other two segments. Not to mention the structural shift in economies like China's -- from investment-based to consumer-driven -- that could jeopardize Caterpillar's growth plans in coming years.

The problem is that there are simply too many unpredictable and uncontrollable external factors steering Caterpillar's fortunes, some of which could have long-term implications. That's already evident in the company's ongoing restructuring moves, which have included plant shutdowns and layoffs on a pretty big scale. Given the backdrop, it's surprising to see Caterpillar shares trading at such high premiums today. I hate to say this, but if investors are already betting on its turnaround, they might have jumped the gun. 

When a great company isn't a great investment

Jason HallThe Coca-Cola Co (KO) is very well-run, sells a product for dollars that it can make for pennies, and has an incredibly strong track record of returning profits and value to investors. Another feather in its cap is that Warren Buffett -- arguably the greatest investor ever -- made his Berkshire Hathaway Coke's largest shareholder. But Coca-Cola is overvalued in my book, and not a stock that I'd buy today.

Coca-Cola trades at around 24 times trailing 12 month earnings. Sure, Coke stock has traded at a much higher P/E ratio in the past, but that statistic has been on an upward trend since shares bottomed out during the financial crisis:

KO PE Ratio (TTM) Chart

KO PE Ratio (TTM) data by YCharts

And it's at a point where I think Coke is going to have a tough time generating enough return to be worthy of a valuation that's higher than the market's average. Key reasons why:

  • Soda consumption is in decline in mature markets. This is a trend that's been going on for years. 
  • Interest rates are set to start climbing again, creating more alternatives for income investors outside dividend stocks. 
  • International growth and new products may not be enough to support Coke "growing" into its current high valuation. 

Investors have been willing to pay a premium for Coke shares in recent years largely for its steady dividend. And while that dividend should be secure and is likely to increase over time, Coke's core business is likely to continue facing weak growth prospects and increased competition from other beverage choices as consumer tastes evolve. 

Bottom line: I admire the company and its management, and it's a company I'd consider buying shares of at the right price. No matter how well-run Coke's business is, it's almost always a mistake to pay a premium price for a company dealing with a secular decline in demand for its most important products.

George Budwell owns shares of BRK-B. Jason Hall owns shares of BRK-B and manages a family account which owns shares of Coca-Cola. Neha Chamaria has no position in any stocks mentioned. The Motley Fool owns shares of and recommends BRK-B. The Motley Fool recommends Coca-Cola. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Caterpillar Stock Quote
Caterpillar
CAT
Coca-Cola Stock Quote
Coca-Cola
KO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.